A 71-Year-Old Woman With High-Risk Ovarian Cancer
Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.
Case: A 71-Year Old Woman With High-Risk Ovarian Cancer
Initial presentation
- A 71-year old woman presented to her PCP for a routine annual checkup, she complains of increasing fatigue
- PMH:
- Hypertension, controlled on a thiazide
- 2017 diagnosed with stage IV ovarian cancer; BRCAwt; underwent TAH/BSO, lymph node dissection, with suboptimal debulking; treated with paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab; achieved CR
Currently
- CA-125, 456 U/mL
- Chest/abdomen/pelvis CT with contrast shows a suspicious lung lesion
- Lung biopsy confirmed recurrent epithelial ovarian cancer
- Molecular testing showed HRD+, LOH high
- ECOG: 0
Treatment and Follow-Up
- She was started referred to an oncologist and started on carboplatin/doxorubicin, treatment was well tolerated for 4 cycles; CA-125 35 U/mL;
- Rucaparib 300 mg BID maintenance was initiated
- At 2 months follow-up
- CA-125 was undetectable
- Chest/abdomen/pelvis CT showed no gross masses or nodes
- Pelvic exam was unremarkable
Recent Videos
Related Content
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024Article
The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More
